Obviously, WS is smarter than you think; they hire bio experts as well as knowledgeable individuals to put out false narratives (e.g. AF). Short-and-distort is a big profitable collusive game... and don't think for one minute that BP isn't somehow involved. Suppressed prices benefit those looking to BO small biotech on the cheap.
If this is from "Wall Street" then you are correct that they don't want anything to do with educating about DCVax. Not a word about dendritic vaccines. Posted 1-10-24
Merck and Bristol Myers have dominated cancer immunotherapy. Who wins oncology’s next era? Merck’s Keytruda and Bristol Myers’ Opdivo have dominated the cancer treatment conversation for a decade. Both will reach the end of their patent-protected monopolies as soon as 2028 in the U.S., pushing the two drugmakers to explore commonly used ways of extending market exclusivity, like combination treatment and formulation changes.
Read More in Pharma
But drugmakers are also working hard to find what comes next. Researchers have struggled to develop successor medicines that stimulate immune attacks on tumor cells as Keytruda and Opdivo do, with Bristol Myers’ combination drug Opdualag an exception to the rule.
The flurry of dealmaking around antibody-drug conjugates in 2023, headlined by Pfizer’s $43 billion acquisition of Seagen, is a sure sign big pharma sees these targeted therapies as a significant new opportunity. Radiopharmaceuticals, which deliver radiation directly to tumor cells, are also drawing significant investment.
Bispecific antibodies, which help immune cells find and destroy tumor cells, have proven successful in treating blood cancers like multiple myeloma and lymphoma. They’ve had less success in solid tumors, although they are still being tested in prostate and lung cancer.
After years of disappointment, cancer vaccines are finally making gains, too. The messenger RNA technology employed by Moderna, BioNTech and others can be used to create personalized treatments that stimulate an immune response to patients’ tumor cells. Key data from Phase 3 trials of Moderna’s Merck-partnered vaccine in melanoma and lung cancer could come in the next couple of years. — Jonathan Gardner
News 
Market Data 
Discover 
